Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLDPF shares. View ZLDPF analyst ratings or view top-rated stocks .

How have ZLDPF shares performed in 2024?

Zealand Pharma A/S's stock was trading at $55.65 at the beginning of the year. Since then, ZLDPF shares have increased by 51.3% and is now trading at $84.19. View the best growth stocks for 2024 here .

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.08. The company had revenue of $3.35 million for the quarter, compared to analyst estimates of $1.97 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 49.78% and a negative net margin of 203.99%.

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ZLDPF

Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ZLDPF Stock Alerts

$84.19

+1.19 (+1.43%)

(As of 04/15/2024 ET)

Compare

Today's Range: $83.91
▼
$84.81
50-Day Range: $67.29
▼
$111.19
52-Week Range: $32.42
▼
$111.44

Volume: 2,025 shs
Average Volume: 2,829 shs
Market Capitalization: $4.34 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Headlines Short Interest

Get Zealand Pharma A/S alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

ZLDPF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZLDPF Stock News Headlines

April 11, 2024 | msn.com

Auckland's newest social supermarket officially opens

April 3, 2024 | markets.businessinsider.com

Unveiling New Zealand's Most Deadly Urban Pest: A Comprehensive Examination

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 31, 2024 | finance.yahoo.com

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

March 18, 2024 | msn.com

Increase in opioid use in New Zealand 'should spark concern' - researchers

March 13, 2024 | markets.businessinsider.com

New Zealand Food Price Inflation Weakest Since 2021

March 1, 2024 | finance.yahoo.com

Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

March 1, 2024 | finance.yahoo.com

Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 1, 2024 | seekingalpha.com

Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript

February 27, 2024 | globenewswire.com

Zealand Pharma convenes its Annual General Meeting 2024

February 26, 2024 | msn.com

Zealand shares surge on liver drug data from Boehringer pact

February 26, 2024 | reuters.com

Zealand Pharma shares surge on liver disease drug trial data

February 19, 2024 | msn.com

New Zealand's birth rate falls to lowest since World War II

February 19, 2024 | msn.com

I Walked All Over New Zealand in Amazon's Best-selling, Comfy Merrell Hiking Shoes — and They're on Sale Today

February 18, 2024 | msn.com

South Korean pharma company SK Biotek to invest up to €35m developing new plant

February 6, 2024 | apnews.com

South Africa 129-7 and trails New Zealand by 382 at lunch on day 3 of the 1st test

February 6, 2024 | msn.com

New Zealand calls for Kiwi pilot to be freed a year after Papua kidnapping

February 6, 2024 | msn.com

New Zealand expects defence capability report in June

February 4, 2024 | msn.com

Call for time limits on Pharmac's drug assessment process

January 31, 2024 | finance.yahoo.com

Total number of shares and voting rights in Zealand Pharma at January 31, 2024

January 17, 2024 | finance.yahoo.com

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

December 29, 2023 | finance.yahoo.com

Total number of shares and voting rights in Zealand Pharma at December 29, 2023

December 23, 2023 | finance.yahoo.com

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

December 23, 2023 | finance.yahoo.com

UPDATE 2-Zealand says US FDA turns down drug for low blood sugar in infants

December 4, 2023 | finance.yahoo.com

Zealand Pharma to highlight obesity pipeline at R&D Event on December 5

November 30, 2023 | finance.yahoo.com

Total number of shares and voting rights in Zealand Pharma at November 30, 2023

See More Headlines

Receive ZLDPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:ZLDPF
Previous Symbol: NASDAQ:ZLDPF
CUSIP: N/A
CIK: N/A
Web: www.zealandpharma.com
Phone: 45-8877-3600
Fax: 45-8877-3898
Employees: 253
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,130,000.00
Net Margins: -203.99%
Pretax Margin: -191.38%
Return on Equity: -49.78%
Return on Assets: -37.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.63
Quick Ratio: 7.59

Sales & Book Value

Annual Sales: $49.75 million
Price / Sales: 87.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.24 per share
Price / Book: 37.58

Miscellaneous

Outstanding Shares: 51,513,000
Free Float: N/A
Market Cap: $4.34 billion
Optionable: Not Optionable
Beta: 0.63

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Adam Sinding Steensberg M.D. (Age 50)
President & CEO
Comp: $1.73M
Ms. Henriette Wennicke (Age 41)
EVP & CFO
Comp: $706.47k
Mr. Ivan Mourits Moller (Age 52)
Executive VP & COO
Dr. David M. Kendall M.D. (Age 63)
Chief Medical Officer and Head of R&D
Mr. Mads Kronborg
Head of Investor Relations & Communication
Mr. Ravinder Singh Chahil (Age 56)
EVP & General Counsel
Ms. Christina Sonnenborg Bredal (Age 39)
Executive VP & Chief People Officer
Dr. Jens Damsgaard Mikkelsen M.D.
Head of Molecular Pharmacology
Dr. Danilo Verge
Head of Global Medical Affairs
Lykke Romer
VP & Head of Finance and Accounting

Key Competitors

View All Competitors

ZLDPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLDPF shares.
View ZLDPF analyst ratings or view top-rated stocks.
How have ZLDPF shares performed in 2024?: Zealand Pharma A/S's stock was trading at $55.65 at the beginning of the year. Since then, ZLDPF shares have increased by 51.3% and is now trading at $84.19.
View the best growth stocks for 2024 here.
How were Zealand Pharma A/S's earnings last quarter?: Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.08. The company had revenue of $3.35 million for the quarter, compared to analyst estimates of $1.97 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 49.78% and a negative net margin of 203.99%.
How do I buy shares of Zealand Pharma A/S?: Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ZLDPF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial